Yahoo
NasdaqGS - Delayed Quote USD

iRhythm Holdings, Inc. (IRTC)

134.00 +7.63 (+6.04%)
At close: 4:00:00 PM EST
134.00 0.00 (0.00%)
After hours: 4:00:48 PM EST
Trade IRTC on Coinbase
IRTC Q3 2026 earnings call
November 5, 2026 at 4:30 PM EST
Chart Range Bar
Loading chart for IRTC
  • Previous Close 126.37
  • Open 128.45
  • Bid 96.79 x 200
  • Ask 166.54 x 200
  • Day's Range 128.00 - 138.36
  • 52 Week Range 100.70 - 192.47
  • Volume 1,192,722
  • Avg. Volume 564,465
  • Market Cap (intraday) 4.417B
  • Beta (5Y Monthly) 1.47
  • PE Ratio (TTM) --
  • EPS (TTM) -0.42
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 171.33
  • Zacks Rating Bearish

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

www.irhythmtech.com

2,400

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IRTC
24.48%
S&P 500 (^GSPC)
12.32%

1-Year Return

IRTC
26.01%
S&P 500 (^GSPC)
13.54%

3-Year Return

IRTC
60.90%
S&P 500 (^GSPC)
76.41%

5-Year Return

IRTC
16.69%
S&P 500 (^GSPC)
64.28%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 224.17M
Earnings -381k
Profit Margin -0.17%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
50M
100M
150M
200M
-6.0%
-4.0%
-2.0%
0.0%
2.0%

Analyst Insights

View More

Analyst Price Targets

140.00
171.33 Average
134.00 Current
196.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/16/2026
Analyst Piper Sandler
Rating Action Initiated
Rating Overweight
Price Action Announces
Price Target 160

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -1.69%

  • Return on Assets (ttm)

    0.65%

  • Return on Equity (ttm)

    -9.63%

  • Revenue (ttm)

    825.34M

  • Net Income Avi to Common (ttm)

    -13.95M

  • Diluted EPS (ttm)

    -0.42

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    591.27M

  • Total Debt/Equity (mrq)

    391.08%

  • Levered Free Cash Flow (ttm)

    81.83M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: